Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $92.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 35.11% year-over-year to $92.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $429.1 million (down 36.69% YoY) and the FY2025 annual result came in at $98.2 million, down 38.77% from the prior year.
• Liabilities and Shareholders Equity retreated to $92.1 million in Q1 2026, from $98.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $286.1 million in Q1 2022 to a low of $92.1 million in Q1 2026.
• A 5-year average of $198.6 million and a median of $199.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 71.85% — and 2025, when it plunged 42.13%.
• Tracing BRNS's Liabilities and Shareholders Equity over 5 years: stood at $270.2 million in 2022, then retreated by 20.61% to $214.5 million in 2023, then retreated by 25.26% to $160.3 million in 2024, then sank by 38.77% to $98.2 million in 2025, then declined by 6.14% to $92.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $92.1 million (Q1 2026), $98.2 million (Q4 2025), and $109.2 million (Q3 2025), per Business Quant data.